HCVD2MAG-67K
MILLIPLEX® Human Cardiovascular Disease (CVD) Magnetic Bead Panel 2 - Cardiovascular Disease Multiplex Assay
The analytes available for this multiplex kit are: ADAMTS13, D-Dimer, GDF-15, Myoglobin, sICAM-1, MPO, P-selectin, Lipocalin-2/NGAL, sVCAM-1, SAA.
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84
Recommended Products
Quality Level
species reactivity
human
manufacturer/tradename
Milliplex®
assay range
accuracy: 88%
(Myoglobin)
accuracy: 90%
(P-selectin)
accuracy: 98%
(GDF-15)
standard curve range: 0.0005-2.5 ng/mL
(GDF-15)
standard curve range: 0.012-50 ng/mL
(Lipocalcin-2/NGAL)
standard curve range: 0.024-100 ng/mL
(Myoglobin & MPO)
standard curve range: 0.085-350 ng/mL
(sICAM-1)
standard curve range: 0.122-500 ng/mL
(sVCAM-1)
standard curve range: 0.244-1,000 ng/mL
(D-dimer, SAA & P-selectin)
standard curve range: 1.221-5,000 ng/mL
(ADAMTS 13)
inter-assay cv: <20%
intra-assay cv: <15%
technique(s)
multiplexing: suitable
detection method
fluorometric (Luminex xMAP)
shipped in
wet ice
General description
Cardiovascular disease, particularly atherosclerotic vascular disease, is a leading cause of global mortality, accounting for 30% of all global deaths (WHO, 2010). Inflammatory mechanisms play a vital role in the initiation, maintenance, and progression of vascular disease with a strong correlation between inflammatory markers and prognosis in acute and chronic coronary artery disease. Numerous studies have demonstrated an association of obesity and diabetes with cardiovascular risk factors.
MILLIPLEX® Human Cardiovascular Disease (CVD) Panel 2 is a 10-plex kit to be used for the simultaneous quantification of any or all of the following analytes in human serum, plasma and tissue/cell lysate and culture supernatant samples: Adamts13, D-dimer, GDF-15, Myoglobin, sICAM-1, MPO, P-selectin, Lipocalin-2/NGAL, sVCAM-1 and SAA. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.
The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.
Panel Type: Cardiovascular
MILLIPLEX® Human Cardiovascular Disease (CVD) Panel 2 is a 10-plex kit to be used for the simultaneous quantification of any or all of the following analytes in human serum, plasma and tissue/cell lysate and culture supernatant samples: Adamts13, D-dimer, GDF-15, Myoglobin, sICAM-1, MPO, P-selectin, Lipocalin-2/NGAL, sVCAM-1 and SAA. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.
The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.
Panel Type: Cardiovascular
Specificity
Cross Reactivty
There was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes in this panel.
There was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes in this panel.
Application
- Analytes: ADAMTS13, D-Dimer, GDF15, sICAM-1, Myeloperoxidase (MPO), Myoglobin, NGAL/Lipocalin-2, sP-selectin, Serum Amyloid A (SAA), sVCAM-1
- Recommended Sample Type: Human serum, plasma, cell/tissue culture supernatants and lysates
- Recommended Sample Dilution: 25 μL per well of 1:100 diluted serum or plasma; tissue/cell culture samples may require dilution in appropriate control medium
- NOTE: D-Dimer cannot be measured in plasma samples
- Assay Run Time: Overnight (16-18 hours) at 2-8°C or 2 hours at room temperature (20-25 °C)
- Research Category: Cardiovascular Disease
- Research Subcategory: Metabolic Disorders
Features and Benefits
Design your multiplex kit by choosing available analytes within this panel.
Other Notes
Please contact Technical Service for linearity of dilution.
Sensitivity: See kit protocol for individual analytes sensitive’s.
Legal Information
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
Target Organs
Respiratory system
Storage Class Code
10 - Combustible liquids
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Alberto Soriano-Maldonado et al.
Journal of clinical medicine, 7(12) (2018-11-28)
This study assessed the effect of 12-week aerobic exercise on arterial stiffness (primary outcome), inflammation, oxidative stress, and cardiorespiratory fitness (secondary outcomes) in women with systemic lupus erythematosus (SLE). In a non-randomized clinical trial, 58 women with SLE were assigned
Lilliam Rocha-Penha et al.
Hypertension (Dallas, Tex. : 1979), 69(6), 1173-1180 (2017-05-04)
Elevated levels of myeloperoxidase have been demonstrated in women with preeclampsia where it may contribute to endothelial dysfunction mediated, in part, by nitric oxide impairment. In this study, we investigated myeloperoxidase in hypertensive disorders of pregnancy and its contribution to
Estefania Simoes et al.
International journal of obesity (2005), 45(4), 879-887 (2021-02-03)
Childhood overweight and obesity are a global concern, with prevalence rising dramatically over the last decades. The condition is caused by an increase in energy intake and reduction of physical activity, leading to excessive fat accumulation, followed by systemic chronic
Priscila Valéria do Carmo Carvalho et al.
Revista da Sociedade Brasileira de Medicina Tropical, 51(3), 277-283 (2018-07-05)
Mortality among HIV patients is 3-15 times higher than that among the general population. Currently, most deaths are due to non-infectious diseases. Chronic inflammation and adverse events due to antiretroviral therapy play crucial roles in increasing cardiovascular risk (CVR). This
Emanuele Marzetti et al.
Frontiers in medicine, 1, 27-27 (2015-01-17)
Chronic, low-grade inflammation and declining physical function are hallmarks of the aging process. However, previous attempts to correlate individual inflammatory biomarkers with physical performance in older people have produced mixed results. Given the complexity of the inflammatory response, the simultaneous
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service